Tildrakizumab for the treatment of probable pyoderma gangrenosum with periosteal involvement

The effect of weight and body mass index (BMI) on choice of biologic therapy and drug survival in patients with psoriasis

Taltz (Ixekizumab) for management of necrobiosis lipoidica diabeticorum: a case presentation

Tuberculosis testing for patients commencing Dupixent (dupilumab): our experience and recommendations

Expectation versus reality: Results of an audit of real-world outcomes of Dupixent (dupilumab) when assessed by quality of life and clinical measures in an outpatient clinic population

Certolizumab pegol for treatment of plaque psoriasis: pooled efficacy outcomes across baseline Psoriasis Area and Severity Index subgroups (CIMPASI-1 and CIMPASI-2)

Rituximab for the treatment of pemphigus vulgaris in Australia: A cost-utility analysis

Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial

Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension